Ponesimod is selective for S1P1, and received FDA approval in 2021 for the treatment of adults with RMS, including CIS, RRMS, and active SPMS, and EMA approval in 2021 for the treatment of adults with active RMS.8, 13. Here, S1PR1 is linked to in situ carcinoma.